Study Results, Product Recalls, Progress on Environmental Goals, Shareholders Resolutions, and Product Launch - Research Report on Intuitive Surgical, Baxter, Thermo Fisher, DaVita, and Mindray

NEW YORK, January 6, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Intuitive Surgical, Inc. (NASDAQ:ISRG), Baxter International Inc. (NYSE:BAX), Thermo Fisher Scientific Inc. (NYSE:TMO),

DaVita HealthCare Partners Inc. (NYSE:DVA), and Mindray Medical International Ltd (NYSE:MR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Intuitive Surgical, Inc. Research Report

On December 19, 2013, Intuitive Surgical, Inc. (Intuitive Surgical) reported results from a national, multi-institutional database study, which showed that readmission and complication rates were significantly lower for robotic-assisted prostate surgery than for open prostate surgery. According to the Company, the retrospective study utilized the National Surgical Quality Improvement (NSQIP) database to analyze data on patients who received a prostatectomy in 2011. The Company stated that a total of 5,471 patients were included in the study, of which 1,097 (20%) had an open procedure and 4,374 (80%) had a minimally invasive robotic-assisted procedure. "Readmissions for Medicare patients alone currently add $17.4 billion each year in health care spending," said Lead Investigator, Robert Nadler MD, Northwestern Medicine Vice Chair of Urology. "The findings from this study show that beyond the patient benefit, robotic-assisted surgery may be relevant to reducing health care costs as it results in reduced readmission rates compared to open surgery." The Full Research Report on Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5f98_ISRG

--

Baxter International Inc. Research Report

On December 23, 2013, Baxter International Inc. (Baxter) announced that it has initiated a voluntary recall to the hospital as well as user level of one lot of 5% Dextrose Injection, USP and four lots of 0.9% Sodium Chloride Injection, USP due to particulate matter found in the solutions. The Company informed that the product codes affected by the aforesaid recall are: a) 2B0089 - 5% Dextrose Injection, USP, 100 ml, Lot # P285288; b) 2B1308 - 0.9% Sodium Chloride Injection, USP, 50 ml, Lot # P297283; c) 2B1302 - 0.9% Sodium Chloride Injection, USP, 100 ml, Lot # P292326 and P293993; and d) 2B1309 - 0.9% Sodium Chloride Injection, USP, 100 ml, Lot # P293514. The Company has notified customers, who are being directed not to use product from the recalled lots. Baxter stated that the affected lots were distributed to customers between May 2012 and October 2013, and the same should be returned to the Company for credit by contacting Baxter Healthcare Center for Service at 1-888-229-0001, Monday through Friday, between 7:00 a.m. and 6:00 p.m. CT. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/163d_BAX

--

Thermo Fisher Scientific Inc. Research Report

On December 17, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) reported that it has released the HM525 NX - a routine clinical cryostat that has 27 cooled specimen positions, including 4 fast freeze positions, allowing a high degree of flexibility when managing specimens. According to the Company, the new HM525 NX also offers: optional or scheduled powerful on-demand, UV disinfection can be initiated through the intuitive icon-driven software to protect the operator; reliable and tested stepper motor technology delivers reproducible section thickness (sectioning range 1-500µm; 64mm vertical specimen stroke); and enhanced user comfort while seated at the cryostat during long cutting sessions by incorporating greater knee space. The Full Research Report on Thermo Fisher Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/45ed_TMO

--

DaVita HealthCare Partners Inc. Research Report  

On December 23, 2013, DaVita, a division of DaVita HealthCare Partners Inc., (DaVita HealthCare) announced progress toward its corporate environmental goals for U.S. operations, which it aims to accomplish by 2015. According to the Company, as of December 31, 2013, it has achieved 9% per treatment reduction in energy consumption since 2010; 14% reduction in water usage, projecting a savings of 400 million gallons of water per year due to operational changes; implementation of paper reduction programs; and development of three new education programs per year for its teammates. Kent Thiry, Co-Chairman and CEO of DaVita HealthCare, said, "One of the pillars in DaVita's Trilogy of Care is caring for our world. By their nature, dialysis operations use a large amount of resources. We aim to reduce our environmental footprint while continuously improving the care provided to dialysis patients each day." The Full Research Report on DaVita HealthCare Partners Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5986_DVA

--

Mindray Medical International Ltd Research Report

On December 19, 2013, Mindray Medical International Ltd. (Mindray) announced shareholder resolutions adopted at its annual general meeting, held in Hong Kong on December 17, 2013. According to the Company, at the meeting the Company's shareholders approved the re-election of incumbent directors Joyce I-Yin Hsu and Wu Qiyao each to serve a three-year term. Additionally, the Company informed that its  shareholders has ratified the appointment of PricewaterhouseCooper as Mindray's independent registered public accounting firm for the fiscal year ending December 31, 2013. The Full Research Report on Mindray Medical International Ltd - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8d4d_MR

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner